OA-11 Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (Dex) Induces Durable Remissions in BCMA-Naïve Patients With Relapsed/Refractory Multiple Myeloma (RRMM): CAMMA 1 Arm B Extended Follow-Up Data

IF 4.1 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2026-09-01 Epub Date: 2026-09-22 DOI:10.1016/S2152-2650(26)03312-4

Andrew Spencer, Hira S. Mian, Kihyun Kim, Laura Paris, Rakesh Popat, Simon J. Harrison, Anna Caroline Hasselbalch, Noa Lavi, Tomas Jelinek, Monika Szarejko, Sebastian Grosicki, Irwindeep Sandhu, Sammy Chebon, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Ameet Mishra, Suzanne Trudel

引用次数: 0

查看原文本刊更多论文

OA-11头孢他单抗联合泊马度胺（Pom）和地塞米松（Dex）诱导BCMA-Naïve复发/难治性多发性骨髓瘤（RRMM）患者持久缓解：CAMMA 1 B组扩展随访数据

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.